The U.S. clinical experience with lomefloxacin, a new once-daily fluoroquinolone

摘要: Abstract Lomefloxacin is a new fluoroquinolone antimicrobial agent that has undergone extensive worldwide clinical evaluation. This report summarizes the safety and efficacy of lomefloxacin in treatment uncomplicated urinary tract infections, complicated acute exacerbations chronic bronchitis, for prophylaxis during surgery. The data presented are an overview all studies conducted United States to date. results have been derived from multiple which patients received or comparative either blinded open-label studies. During course program States, compared with oral norfloxacin, ciprofloxacin, cefaclor, as well parenteral cefotaxime. In instances, once-daily administration was equally effective statistically significantly superior and/or bacteriologic these agents. addition, comparators were administered two three times per day, except surgical studies, single doses each antibiotic preoperatively. These attest value convenience simplicity dosing regimen lomefloxacin. program, tolerated, most adverse events mild moderate severity. general, incidence subjects receiving comparable observed treated comparator drugs. common related gastrointestinal (nausea diarrhea), skin appendages (photosensitivity), central nervous system (dizziness headache).